FDA Lifts Hold On Biodel Diabetes Study; Shares Jump
This article was originally published in Scrip
Shares of Biodel Inc. leaped 16.3% on Oct. 13 on news the FDA had lifted the partial clinical hold on the company's randomized, open-label, parallel group Phase IIb trial, known as Study 3-250, which was testing the company's ultra-rapid-acting concentrated insulin formulation candidate BIOD-531 in patients with insulin-treated type 2 diabetes versus Eli Lilly & Co.'s Humalog (insulin lispro) Mix 75/25.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.